AF-45

• UNSPSC Description:

  AF-45 inhibits IRAK4 and IRAK1, with IC50s of 128 nM and 1765 nM. AF-45 inhibits the release of IL-6 and TNF-α in macrophages, with IC50s of 0.53-1.54 μM and 0.6-2.75 μM. AF-45 is also an inhibitor for NF-κB/MAPK signaling pathway. AF-45 exhibits anti-inflammatory activities against DSS-induced ulcerative colitis and Lipopolysaccharide (HY-D1056)-induced acute lung injury in mouse model. AF-45 exhibits good pharmacokinetic characteristics in rat models[1].

• Target Antigen:

  IRAK; NF-κB; p38 MAPK; TNF Receptor

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Immunology/Inflammation;MAPK/ERK Pathway;NF-κB

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/af-45.html

• Smiles:

  COC1=CC2=C(N=CN=C2O[C@H]3CC[C@@H](N)CC3)C=C1OCC4=CC=CC=C4

• Molecular Weight:

  379.45

• References & Citations:

  [1]Zou Y, et al., Fragment-Based Anti-inflammatory Agent Design and Target Identification: Discovery of AF-45 as an IRAK4 Inhibitor to Treat Ulcerative Colitis and Acute Lung Injury. J Med Chem. 2024 Jun 24.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported